Myron Z. Holubiak


Mr. Holubiak has been a director since 2010. He serves as President, Chief Executive Officer and a director of Citius Pharmaceuticals, a late-stage drug development company focused on critical care drug products, and successor by merger to Leonard-Meron Biosciences. Mr. Holubiak is the former President of Roche Laboratories, USA, a major research-based pharmaceutical company, where he held executive, operational and sales and marketing positions during a 19-year tenure. From September 2002 until June 2016, Mr. Holubiak served on the board of directors of BioScrip, a publicly traded company and a leading home infusion provider with nationwide pharmacy and nursing capabilities, and was chairman of the board of Bioscrip from April 2012 until June 2016. From May 2007 to January 2014, Mr. Holubiak was president of 1-800-DOCTORS, a private physician finder company and a member of its board of directors until September 2017. Mr. Holubiak is a director of bioAffinity Technologies, a private cancer screening and diagnostics company, and former director of Intellicell Biosciences, a publicly traded regenerative medicine company. Mr. Holubiak is also a trustee of the Academy of Managed Care Pharmacy Foundation and a Lifetime Honorary Member of AMCP. Mr. Holubiak received his BS in Molecular Biology and Biophysics from the University of Pittsburgh. Mr. Holubiak has received advanced business training from the Harvard Business School, the London School of Economics and the Centre for Health Economics at the University of York.

Independent Director